Sentry has learned of a drug manufacturer update that impacts our clients. Amgen recently changed its distribution model for the drug Neulasta®. The drug will now be distributed through the wholesaler specialty divisions for 340B and non-340B Covered Entities.
Sentry encourages our clients to read the related update from Apexus and stay alerted to any news related to 340B participation.
For current clients, Sentry has posted a more in-depth response to this drug procurement update that can be viewed on the main Datanex page after logging in to Sentry’s system.